DIA study links more oversight to better orphan drug access

07/30/2013 | PharmExec.com

A study sponsored by DIA found that countries with more regulatory structures for advancing treatments for rare diseases have greater access by patients to orphan drugs compared with countries with less extensive regulatory frameworks. The U.S. did not do as well as France, Spain, the U.K. and Germany in providing access to 13 orphan treatments, according to the study.

View Full Article in:

PharmExec.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Chicago, IL
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC